SMS Pharmaceuticals Ltd

SMS Pharma. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

SMS Pharmaceuticals Ltd

₹ 369 -2.15%
29 May - close price
smspharma.com BSE: 532815 NSE: SMSPHARMA
About

SMS Pharmaceuticals Ltd is a diversified and integrated pharmaceutical company with interests in Active Pharmaceutical Ingredients (API) and Intermediates.[1]

Key Points

Product Portfolio
It is an integrated pharmaceutical company specializing in Active Pharmaceutical Ingredients (API) and complex Intermediates, under various therapeutic categories including Anti-ulcer, anti-fungal, anti-migraine, anti-viral, anti-diabetic, anti-retroviral, etc. with global leadership position in 10+ therapeutic products. The company offers 45+ products to 800+ customers across 75+ countries. [1] [2]

Website BSE NSE
  • Market Cap ₹ 3,458 Cr.
  • Current Price ₹ 369
  • High / Low ₹ 448 / 208
  • Stock P/E 39.5
  • Book Value ₹ 85.9
  • Dividend Yield 0.11 %
  • ROCE 12.9 %
  • ROE 11.9 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • Stock is trading at 4.30 times its book value
  • Company has a low return on equity of 10.8% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
149 135 167 161 246 164 197 173 248 196 242 210 238
126 109 139 133 212 131 165 140 207 157 194 167 198
Operating Profit 23 27 28 29 33 33 32 33 41 39 48 44 40
OPM % 16% 20% 17% 18% 14% 20% 16% 19% 17% 20% 20% 21% 17%
1 1 1 1 2 1 1 2 1 1 1 4 3
Interest 6 6 6 6 6 5 5 4 5 6 6 6 5
Depreciation 8 8 8 8 8 8 9 9 9 10 10 10 10
Profit before tax 11 13 15 16 22 22 20 23 29 24 34 31 27
Tax % 24% 29% 21% 26% 26% 25% 28% 24% 29% 24% 26% 25% 23%
8 9 12 12 16 16 14 17 21 18 25 23 21
EPS in Rs 0.95 1.10 1.42 1.44 1.88 1.93 1.68 2.03 2.33 2.05 2.68 2.49 2.23
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
587 611 438 463 465 412 563 520 522 709 783 887
500 522 363 369 375 332 442 405 467 592 643 716
Operating Profit 86 89 75 93 90 80 121 115 55 117 140 171
OPM % 15% 15% 17% 20% 19% 19% 22% 22% 10% 16% 18% 19%
16 4 1 2 3 5 3 5 5 4 6 8
Interest 18 17 16 15 12 12 11 19 22 24 19 23
Depreciation 17 19 19 20 19 22 22 32 32 32 34 40
Profit before tax 67 56 42 60 62 51 91 69 6 66 93 116
Tax % 48% 26% 14% 33% 34% 36% 33% 1% 26% 25% 27% 25%
35 42 36 40 41 33 61 68 4 49 68 88
EPS in Rs 4.15 4.92 4.20 4.78 4.89 3.86 7.20 8.03 0.48 5.83 7.71 9.35
Dividend Payout % 5% 4% 5% 5% 5% 6% 4% 4% 62% 7% 5% 4%
Compounded Sales Growth
10 Years: 4%
5 Years: 10%
3 Years: 19%
TTM: 13%
Compounded Profit Growth
10 Years: 8%
5 Years: 8%
3 Years: 177%
TTM: 28%
Stock Price CAGR
10 Years: 17%
5 Years: 17%
3 Years: 64%
1 Year: 39%
Return on Equity
10 Years: 11%
5 Years: 10%
3 Years: 11%
Last Year: 12%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 8 8 8 8 8 8 8 8 8 8 9 9
Reserves 246 286 254 293 331 359 420 485 487 562 664 795
167 204 149 146 144 157 255 263 254 281 311 365
119 158 89 72 93 103 147 126 165 217 202 211
Total Liabilities 540 656 501 519 577 627 830 883 914 1,068 1,186 1,381
277 370 290 279 281 280 457 438 412 437 533 534
CWIP 29 13 8 8 18 42 7 11 33 30 35 116
Investments 13 21 37 45 45 45 45 45 45 45 45 52
221 252 166 187 232 259 321 389 424 556 573 679
Total Assets 540 656 501 519 577 627 830 883 914 1,068 1,186 1,381

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
59 61 73 32 50 40 90 45 22 50 82 61
-55 -79 -39 -17 -35 -43 -152 -27 -30 -52 -123 -132
-10 27 -33 -15 -13 -2 92 -12 -32 31 47 76
Net Cash Flow -6 9 1 0 2 -5 31 6 -39 29 5 4
Free Cash Flow 11 -27 50 23 15 -3 -61 18 -7 -2 -42 -64
CFO/OP 75% 93% 110% 46% 70% 65% 88% 52% 49% 56% 73% 50%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 37 36 18 19 20 43 68 34 104 122 95 89
Inventory Days 81 106 114 135 170 191 148 333 243 201 238 259
Days Payable 58 79 82 49 59 66 70 97 117 130 95 89
Cash Conversion Cycle 61 63 50 105 131 169 146 270 230 192 238 259
Working Capital Days 19 19 -2 27 39 57 48 94 104 85 88 98
ROCE % 21% 16% 13% 18% 16% 13% 17% 12% 4% 11% 12% 13%

Insights

In beta
Mar 2015 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Total Employees
Count

Log in to view insights

Please log in to see hidden values.

Login
Cumulative DMF Filings
Count
Anti-Inflammatory (Ibuprofen) Sales Volume
MT
Global Presence (Countries)
Count
R&D Scientist Strength
Count
Total Reactor Capacity
KL
Anti-Diabetic Sales Volume
MT
Net Asset Turnover
Times
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

2 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
64.32% 64.32% 64.32% 64.67% 64.67% 64.67% 64.67% 66.27% 66.27% 68.07% 68.07% 68.07%
0.67% 0.60% 0.59% 0.17% 0.18% 0.52% 0.31% 0.08% 0.03% 0.28% 0.04% 0.31%
0.00% 0.00% 0.00% 1.98% 2.13% 2.55% 2.55% 2.43% 3.03% 2.88% 3.21% 3.02%
35.01% 35.07% 35.10% 33.18% 33.03% 32.27% 32.47% 31.23% 30.68% 28.77% 28.69% 28.60%
No. of Shareholders 24,65325,24625,34130,14031,78033,13634,97335,33233,65234,15734,37832,397

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls